سعر لاكتيولوز -ايه يو جي فارما 3.35جم/5مل شراب 320 مل 2024

Lactulose-aug pharma 3.35gm/5ml syrup 320ml: lactulose 3.35 g/5 ml oral syrup, 320 ml bottle (Aug pharma, Egypt); osmotic laxative.

• Treatment of constipation.Population: Adults and childrenelectronic medicines compendium (emc)
• Treatment of hepatic encephalopathy (hepatic coma).Population: Adultselectronic medicines compendium (emc)

• Very common: diarrhoea. Common: flatulence, abdominal pain, nausea, vomiting. Uncommon: electrolyte imbalance due to diarrhoea. Not known: hypersensitivity reactions, rash, pruritus, urticaria (post-marketing). Flatulence in the first days usually disappears.International label, equivalent formulation · electronic medicines compendium (emc)

• Hypersensitivity to lactulose or any excipient; galactosaemia; gastrointestinal obstruction, perforation or risk of perforation.International label, equivalent formulation · electronic medicines compendium (emc)

• Painful abdominal symptoms of undetermined cause should be evaluated before treatment to exclude perforation or obstruction. Chronic use of unadjusted doses and misuse can cause diarrhoea and electrolyte disturbance. The higher doses used in hepatic encephalopathy may need to be considered in diabetics. The UK product contains lactose, galactose and fructose residues: not for patients with hereditary galactose or fructose intolerance, total lactase deficiency or glucose-galactose malabsorption; use with care in lactose intolerance. Use of laxatives in children should be exceptional and under medical supervision.International label, equivalent formulation · electronic medicines compendium (emc)
• Theoretical hazard during electrocautery at proctoscopy or colonoscopy because of hydrogen gas accumulation; patients on lactulose should have thorough bowel cleansing with a non-fermentable solution. Infants receiving lactulose may develop hyponatraemia and dehydration.General active-ingredient information · DailyMed (U.S. National Library of Medicine)

• Oral anti-infectives (e.g. neomycin)Elimination of colonic bacteria may interfere with lactulose degradation and colonic acidification; monitor the patient closely during concomitant oral anti-infective therapy.DailyMed (U.S. National Library of Medicine)
• Non-absorbable antacidsMay inhibit the desired lactulose-induced drop in colonic pH; consider a possible lack of effect.DailyMed (U.S. National Library of Medicine)

• No effects during pregnancy are anticipated since systemic exposure to lactulose is negligible; can be used during pregnancy.International label, equivalent formulation · electronic medicines compendium (emc)
• No effects on the breastfed infant are anticipated since maternal systemic exposure is negligible; can be used during breastfeeding.International label, equivalent formulation · electronic medicines compendium (emc)

• Lactulose: Broken down by colonic bacteria into low-molecular-weight organic acids that lower colonic pH and, by an osmotic effect, increase the volume of colonic contents and stimulate peristalsis; in hepatic encephalopathy it also traps ammonia in ionic form and alters bacterial nitrogen metabolism (UK SmPC 5.1).